Physician profile
John Yager
NPI 1700248119
$5,303.42
in general payments reported to CMS, 2019-2025
33 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $38.98 · 2021: $597 · 2022: $833 · 2023: $1,006 · 2024: $1,288 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,677.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,102.34 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $743.54 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $742.78 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $472.63 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $210.10 | 2023-2025 | |
| Amgen INC. | $182.78 | 2022-2024 | Repatha, Otezla, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.20 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $172.45 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Ucb, INC. | $157.14 | 2019-2024 | Nayzilam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.29 | 2022-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $124.77 | 2023-2025 | Gvoke Hypopen |
| Pfizer INC. | $120.34 | 2019-2024 | |
| Lundbeck LLC | $112.79 | 2021-2025 | Vyepti, Rexulti |
| Verona Pharma, INC. | $90.04 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $89.34 | 2021-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $84.31 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.56 | 2024-2025 | Xifaxan |
| Dexcom, INC. | $73.66 | 2022-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $66.54 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $49.14 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $48.47 | 2021-2022 | |
| Antares Pharma, INC. | $42.56 | 2025 | Xyosted |
| Sumitomo Pharma America, INC. | $38.42 | 2025 | Gemtesa |
| Tolmar, INC. | $31.21 | 2025 | Jatenzo |
| Eisai INC. | $24.02 | 2024 | |
| Mylan Specialty L.P. | $23.12 | 2022 | |
| Axsome Therapeutics, INC. | $17.96 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $17.75 | 2023 | Krystexxa |
| Medtronic, INC. | $17.54 | 2025 | Interstim |
| Cipher Pharmaceuticals US LLC | $17.17 | 2025 | Spinosad, Natroba |
| Exact Sciences Corporation | $14.72 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $13.88 | 2019 | |
| Boston Scientific Corporation | $13.86 | 2025 | Bodyguardian |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Yager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.